Published in Diagn Microbiol Infect Dis on May 01, 1999
Terrestrial small mammals as reservoirs of Mycobacterium ulcerans in benin. Appl Environ Microbiol (2010) 1.13
"Mycobacterium tilburgii" infections. Emerg Infect Dis (2006) 0.94
Mycobacterium liflandii infection in European colony of Silurana tropicalis. Emerg Infect Dis (2007) 0.81
Disseminated Mycobacterium genavense Infection in Patient with Adult-Onset Immunodeficiency. Emerg Infect Dis (2017) 0.75
Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol (1995) 15.19
Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia, and The Netherlands: usefulness of DNA typing for global tuberculosis epidemiology. J Infect Dis (1995) 6.95
Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother (1994) 5.64
Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet (1993) 5.52
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol (1997) 5.28
Diagnosis of Mycobacterium microti infections among humans by using novel genetic markers. J Clin Microbiol (1998) 4.83
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Insects in the transmission of Mycobacterium ulcerans infection. Lancet (1999) 4.46
Disseminated "Mycobacterium genavense" infection in patients with AIDS. Lancet (1992) 4.42
Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet (1996) 4.22
Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis (1995) 3.83
Brief report: disseminated osteomyelitis from Mycobacterium ulcerans after a snakebite. N Engl J Med (1993) 3.75
Proposed minimal standards for the genus Mycobacterium and for description of new slowly growing Mycobacterium species. Int J Syst Bacteriol (1992) 3.65
Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother (1997) 3.55
Identification of Mycobacterium species by using amplified ribosomal DNA restriction analysis. J Clin Microbiol (1993) 3.38
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med (1995) 3.09
Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis (1999) 3.08
DNA probes demonstrate a single highly conserved strain of Mycobacterium avium infecting AIDS patients. Lancet (1989) 2.91
Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis (2000) 2.71
Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis (1987) 2.71
IS901, a new member of a widespread class of atypical insertion sequences, is associated with pathogenicity in Mycobacterium avium. Mol Microbiol (1991) 2.64
A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans. J Clin Microbiol (2000) 2.43
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
16S rRNA sequence diversity in Mycobacterium celatum strains caused by presence of two different copies of 16S rRNA gene. J Clin Microbiol (1998) 2.33
Geographically distinct isolates of Mycobacterium leprae exhibit no genotypic diversity by restriction fragment-length polymorphism analysis. Mol Microbiol (1990) 2.25
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis (2001) 2.24
Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis (2004) 2.20
Biologically distinct subtypes of Mycobacterium avium differ in possession of insertion sequence IS901. J Clin Microbiol (1992) 2.18
Two different 16S rRNA genes in a mycobacterial strain. J Clin Microbiol (1996) 2.17
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med (1994) 2.16
Cloning and analysis of the K1 capsule biosynthesis genes of Escherichia coli: lack of homology with Neisseria meningitidis group B DNA sequences. Infect Immun (1983) 2.15
Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis (2004) 2.08
Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med (2008) 2.03
[HIV epidemic: an end to exceptional regulation? Response to the article which appeared under this title in the Revue médicale de la Suisse romande (112, 239-241, 1991)]. Rev Med Suisse Romande (1992) 2.02
Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort Study. Ann Intern Med (1991) 2.02
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
Pulmonary tuberculosis in prisons of the ex-USSR state Georgia: results of a nation-wide prevalence survey among sentenced inmates. Int J Tuberc Lung Dis (2000) 2.01
Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol (2007) 1.98
Detection and identification of mycobacteria by DNA amplification and oligonucleotide-specific capture plate hybridization. J Clin Microbiol (1995) 1.94
Mycobacterium genavense sp. nov. Int J Syst Bacteriol (1993) 1.88
Evaluation of mycobacteria growth indicator tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital. J Clin Microbiol (2001) 1.85
Rapid identification of Mycobacteria to the species level using INNO-LiPA Mycobacteria, a reverse hybridization assay. J Clin Microbiol (2001) 1.85
Effects of decontamination methods and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol (1998) 1.85
Comparison of two PCRs for detection of Mycobacterium ulcerans. J Clin Microbiol (1999) 1.82
In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother (1998) 1.80
Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerg Infect Dis (2001) 1.75
[Epidemiology of ulcers due to Mycobacterium ulcerans]. Ann Soc Belg Med Trop (1989) 1.74
Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis (1998) 1.72
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer (2008) 1.70
Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 1.69
Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans. J Clin Microbiol (2002) 1.67
Mycobacterium ulcerans infection (Buruli ulcer): first reported patients in Togo. Br J Dermatol (1996) 1.67
Red fingers syndrome in patients with HIV and hepatitis C infection. Lancet (1996) 1.66
Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol (1998) 1.65
Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis (1999) 1.63
[Buruli ulcer: risk of bone involvement! Apropos of 33 cases observed in Benin]. Med Trop (Mars) (2000) 1.63
Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis (2007) 1.62
Simple procedure for drug susceptibility testing of Mycobacterium tuberculosis using a commercial colorimetic assay. Eur J Clin Microbiol Infect Dis (1999) 1.59
Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS (1992) 1.55
Clinical relevance of cytomegalovirus viraemia(*,†). HIV Med (2011) 1.55
The use of IS2404 restriction fragment length polymorphisms suggests the diversity of Mycobacterium ulcerans from different geographical areas. Am J Trop Med Hyg (2001) 1.54
Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Int J Tuberc Lung Dis (2001) 1.53
Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis (1993) 1.52
Reasons for failure of prevention of Toxoplasma encephalitis. Swiss HIV Cohort Study. AIDS (1996) 1.52
Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun (2001) 1.50
In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother (2000) 1.50
Evaluation of PCR-restriction profile analysis and IS2404 restriction fragment length polymorphism and amplified fragment length polymorphism fingerprinting for identification and typing of Mycobacterium ulcerans and M. marinum. J Clin Microbiol (2001) 1.49
Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health (2004) 1.48
Characterization of the virulence of Mycobacterium avium complex (MAC) isolates in mice. Clin Exp Immunol (1994) 1.47
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS (1998) 1.46
A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis (1999) 1.46
Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS (2000) 1.44
[Mycobacterium ulcerans cutaneous infections: Buruli ulcers]. Med Trop (Mars) (1995) 1.44
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS (1999) 1.44
Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis (2005) 1.43
Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric method. Antimicrob Agents Chemother (2001) 1.40
Studies on Mycobacterium chelonei. J Med Microbiol (1972) 1.40
Fatty and mycolic acids of Mycobacterium malmoense. J Clin Microbiol (1988) 1.40
Further studies on African strains of Mycobacterium tuberculosis: comparison with M. bovis and M. microti. Ann Soc Belges Med Trop Parasitol Mycol (1970) 1.38
Mycobacteriosis caused by Mycobacterium genavense in birds kept in a zoo: 11-year survey. J Clin Microbiol (1996) 1.38
Rhodococcus equi infection in 3 AIDS patients. Acta Clin Belg (1996) 1.38
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med (2006) 1.38
HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med (1997) 1.35
Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS (1990) 1.33
Limitations and requirements for quality control of sputum smear microscopy for acid-fast bacilli. Int J Tuberc Lung Dis (1998) 1.32
First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis (2009) 1.28
Anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis patients in Cotonou, Benin. Int J Tuberc Lung Dis (2007) 1.27
Evaluation of amplified fragment length polymorphism analysis for inter- and intraspecific differentiation of Mycobacterium bovis, M. tuberculosis, and M. ulcerans. J Clin Microbiol (2000) 1.26
Drug resistance monitoring: combined rates may be the best indicator of programme performance. Int J Tuberc Lung Dis (2004) 1.24
Bleach sedimentation method for increased sensitivity of sputum smear microscopy: does it work? Int J Tuberc Lung Dis (2000) 1.20